Prothena Corp. (PRTA) Insider Karin L. Walker Sells 12,000 Shares
Prothena Corp. (NASDAQ:PRTA) insider Karin L. Walker sold 12,000 shares of the company’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $61.10, for a total transaction of $733,200.00. Following the completion of the sale, the insider now directly owns 7,000 shares in the company, valued at $427,700. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
Prothena Corp. (NASDAQ:PRTA) opened at 62.07 on Thursday. The firm’s 50-day moving average is $55.11 and its 200-day moving average is $46.57. Prothena Corp. has a 52-week low of $28.20 and a 52-week high of $76.42. The firm’s market capitalization is $2.13 billion.
Prothena Corp. (NASDAQ:PRTA) last released its quarterly earnings data on Tuesday, August 2nd. The company reported ($1.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by $0.27. Prothena Corp. had a negative return on equity of 28.15% and a negative net margin of 8,628.11%. The company had revenue of $0.33 million for the quarter, compared to analyst estimates of $0.39 million. Prothena Corp.’s quarterly revenue was up 22.2% compared to the same quarter last year. On average, analysts anticipate that Prothena Corp. will post ($4.25) earnings per share for the current year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/prothena-corp-prta-insider-karin-l-walker-sells-12000-shares.html
PRTA has been the topic of several recent research reports. Royal Bank Of Canada reaffirmed a “buy” rating on shares of Prothena Corp. in a report on Wednesday, June 22nd. Wedbush reiterated an “outperform” rating and issued a $77.00 target price on shares of Prothena Corp. in a research note on Tuesday, July 5th. Barclays PLC boosted their target price on shares of Prothena Corp. from $60.00 to $70.00 and gave the company an “overweight” rating in a research note on Thursday, August 4th. Finally, Credit Suisse Group AG reiterated a “buy” rating and issued a $65.00 target price on shares of Prothena Corp. in a research note on Sunday, September 11th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $76.80.
Institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP raised its position in shares of Prothena Corp. by 29.0% in the first quarter. Wellington Management Group LLP now owns 3,216,685 shares of the company’s stock worth $132,398,000 after buying an additional 722,889 shares during the period. BlackRock Institutional Trust Company N.A. raised its position in shares of Prothena Corp. by 9.8% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 846,698 shares of the company’s stock worth $34,850,000 after buying an additional 75,385 shares during the period. BlackRock Fund Advisors raised its position in shares of Prothena Corp. by 10.0% in the first quarter. BlackRock Fund Advisors now owns 1,248,919 shares of the company’s stock worth $51,406,000 after buying an additional 113,332 shares during the period. Bellevue Group AG acquired a new position in shares of Prothena Corp. during the first quarter worth about $1,276,000. Finally, BlackRock Group LTD raised its position in shares of Prothena Corp. by 23.1% in the first quarter. BlackRock Group LTD now owns 19,094 shares of the company’s stock worth $785,000 after buying an additional 3,577 shares during the period.
About Prothena Corp.
Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis (PRX003).
Receive News & Ratings for Prothena Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corp. and related companies with MarketBeat.com's FREE daily email newsletter.